Osilodrostat phosphate is under clinical development by Recordati and currently in Phase II for Cushing’s Syndrome. According to GlobalData, Phase II drugs for Cushing’s Syndrome have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Osilodrostat phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Osilodrostat phosphate overview
Osilodrostat Phosphate (Isturisa) belongs to benzonitriles, acts as an corticosteroid. It is formulated as film coated tablets for oral route of administration. Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults, and for patients with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.
Osilodrostat (LCI-699) is under development for the treatment of pituitary ACTH hypersecretion (Cushing Disease), Cushing's syndrome. It is administered orally and acts by targeting aldosterone synthase. It was also under development for the treatment of primary hyperaldosteronism, heart failure, hypertension including essential hypertension, congestive heart failure and resistant hypertension.
Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.
For a complete picture of Osilodrostat phosphate’s drug-specific PTSR and LoA scores, buy the report here.